Rocket Pharmaceuticals: Despite FDA Clinical Hold On RP-A501, Prospects Remain Intact

2025-05-28 14:18:41 ET

Summary

• FDA places clinical hold of RP-A501 for the treatment of patients with Danon disease due to a patient death.
• A path forward of RP-A501 for the treatment of patients with Danon disease might still be possible if the culprit was the introduction of the novel immune suppression agent.
• RP-A601 is a gene therapy being developed in a phase 1 study for the treatment of patients with PKP2 Arrhythmogenic Cardiomyopathy.
• RP-A601 might not possibly fall into safety issue because of the differentiated vector of AAVrh.74; plus also because this program doesn't include a pre-treatment regimen of C3 inhibitor.

Rocket Pharmaceuticals ( RCKT ) announced that it had a major roadblock with the development of its AAV9 gene therapy RP-A501 for the treatment of patients with Danon disease. In particular, it was announced that one patient in particular experienced a serious adverse event [SAE] of capillary leak syndrome. Upon this SAE being discovered, there were two different actions taken since then. The first of which is that the company chose to voluntarily pause further dosing of the ongoing pivotal phase 2 trial....

Read the full article on Seeking Alpha

For further details see: